Finally, based on the potential active immune microenvironment of the HER2 (+) tumors and the known synergistic effect of anti-HER2 treatment and immunotherapy, such a combination in endometrial carcinoma may be a future development. The gene discussed is ERBB2; the disease is endometrial carcinoma.